Thomas Schwartz, MD
Psychiatry · Syracuse, NYNPI 1447286406
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,088 of the $4,137 with a category attached, or 98.8%. Janssen Scientific Affairs, LLC accounts for 98.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $3,270 and has fallen 74.6% since, to $831 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $689.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$4K
- Abbott$22
- Neuronetics, Inc.$14
- E.r. Squibb & Sons, L.L.C.$14
Across 23 payments — averaging $2453.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$56K
What the payments were for
- Consulting fees$4,08899%
- Food & beverage$361%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 3 | $4,088 |
| Abbott | 1 | $22 |
| Neuronetics, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$4,088
How this compares
$4,137 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $93,117 |
| Modafinil | 11 | $439 |
| Mirtazapine | 31 | $421 |
| Trazodone Hcl | 13 | $42 |
| Clonazepam | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Syracuse
- Ahmed NizarSyracuse$763K
- Steven NaprawaSyracuse$561K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.